This segment focuses on the development and commercialization of Human Acellular Vessels (HAVs) for vascular repair, reconstruction, and replacement. Research and development activities include ongoing clinical trials for HAVs in various applications, such as vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease. The core technology involves bioengineering human tissues that can be implanted without triggering an immune response. Patient impact is significant, offering potential solutions for patients with critical vascular conditions. Market positioning is based on the unique properties of HAVs, which aim to provide a more durable and biocompatible alternative to existing treatments. Future opportunities include expansion into new therapeutic areas and geographic markets. Regulatory and clinical aspects are critical, with ongoing efforts to secure approvals and demonstrate long-term safety and efficacy. Partnerships with healthcare providers and medical device companies are essential for market access and distribution.

This segment is dedicated to developing a BioVascular Pancreas (BVP™) for the treatment of Type 1 diabetes. Research and development efforts involve collaborations with organizations like JDRF and Pluristyx to develop insulin-producing cells within a bioengineered vascular structure. The technology utilizes iPSCs (induced pluripotent stem cells) and gene editing to create a functional BVP™. The therapeutic area is Type 1 diabetes, aiming to provide a potential cure by replacing damaged pancreatic cells. Patient impact could be transformative, offering a potential for insulin independence. Market positioning is based on the unmet need for a long-term solution for Type 1 diabetes. Future opportunities include clinical trials and regulatory approvals. Regulatory aspects involve working with the FDA to ensure safety and efficacy. Partnerships with research institutions and patient advocacy groups are crucial for advancing this innovative therapy.